posted
Nutra Pharma Reports Preclinical Results of RPI-78M in Multiple Sclerosis to Be Presented at Scientific Meeting
BOYNTON BEACH, Fla.--Feb. 9, 2006--Nutra Pharma Corp. (OTCBB:NPHC), a biotechnology company that owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis, has announced that the studies using RPI-78M in an animal model of Multiple Sclerosis (MS) have been accepted for presentation and publication. RPI-78M is the lead drug candidate of Nutra Pharma's holding, ReceptoPharm, Inc. and is being studied in preclinical assays for its efficacy in treating MS.